Pilot Bioequivalence Studies
A small, fast study that answers the most expensive question in generics development: is this formulation ready for a pivotal trial? De-risk your pivotal spend with real variability data.
Count
Methods
Facility
Fast Turnaround
What Is a Pilot Bioequivalence Study?
A pilot bioequivalence study is a small preliminary study — typically around 12 subjects — run before the pivotal BE trial. It measures how variable your test formulation really is against the reference product, validates the bioanalytical method on real study samples, and confirms the sampling schedule captures the full concentration-time profile.
The output is the number every sponsor needs before committing serious budget: a realistic estimate of intra-subject variability, which drives the sample size of the pivotal study. Skipping the pilot and guessing that number is how pivotal studies fail — an underpowered pivotal study on a variable formulation is the most expensive mistake in generic development.
We run pilot studies at our DCGI-mandated clinical research centre in Pune with in-house LC-MS/MS bioanalysis, so the pilot flows directly into the pivotal study — same facility, same method, same team, no handover losses.
Pilot vs Pivotal Bioequivalence Studies
Two studies, two different jobs — the pilot buys information, the pivotal buys approval.
| Aspect | Pilot BE Study | Pivotal BE Study |
|---|---|---|
| Purpose | Estimate variability, test the method and sampling schedule | Demonstrate bioequivalence for regulatory approval |
| Typical size | Around 12 subjects | 18–36+ subjects, driven by pilot variability data |
| Statistical goal | Point estimates and variability — no pass/fail claim | 90% CI of Cmax & AUC ratios within 80.00–125.00% |
| Regulatory role | Supportive data; de-risks the program | The study regulators review for approval |
| Cost & duration | Fraction of pivotal cost, weeks | Full study budget, months |
What a Pilot Study Answers
Intra-Subject Variability
The CV% that determines your pivotal sample size — measured, not assumed from literature.
Formulation Signal
An early read on whether the test formulation tracks the reference closely enough to proceed.
Method Confirmation
The LC-MS/MS method proven on real incurred samples, not just spiked calibrators.
Sampling Schedule Check
Confirmation that timepoints capture Cmax and the elimination phase for your molecule.
Go / No-Go Economics
Reformulate for thousands now instead of failing a pivotal study worth many times more.
Pivotal-Ready Protocol
Pilot learnings written straight into the pivotal protocol by the same scientific team.
Pilot Data You Can Actually Build On
Pilot conclusions are only as good as the assay behind them. Samples are analyzed on coupled LC-MS/MS units from AB Sciex against our library of 75+ validated methods — recent work includes Semaglutide validated at 1.000 ng/mL in human plasma. The same validated method then carries your pivotal study, so nothing is re-learned and nothing drifts between studies.
Pilot Study Process
- 01
Feasibility & Design
Molecule review, reference product strategy, subject count, and sampling schedule agreed with your team.
- 02
Ethics Approval
Independent ethics committee submission and clearance, handled end to end by our regulatory team.
- 03
Clinical Conduct
Screening, dosing, and timed sampling in our monitored clinical unit — typically a single short confinement cycle per period.
- 04
Bioanalysis & PK
LC-MS/MS analysis, pharmacokinetic parameters, and intra-subject variability estimation.
- 05
Report & Pivotal Plan
A concise pilot report with a clear recommendation — proceed, adjust the formulation, or refine the design — plus a ready pivotal protocol.
Why Sponsors Choose Us for Pilot BE Studies
- DCGI-mandated, ANVISA-approved clinical research facility
- Pilot and pivotal under one roof — same team, method, and beds
- 75+ validated LC-MS/MS methods ready to deploy
- Honest go/no-go recommendations, not automatic green lights
- Variability data powering an accurately sized pivotal study
- Fast ethics submissions and short confinement cycles
Pilot BE Studies — Frequently Asked Questions
1. What is the purpose of a pilot bioequivalence study?
2. How many subjects does a pilot BE study need?
3. Is a pilot study mandatory before a pivotal BE study?
4. Can pilot study data be used for regulatory approval?
5. How long does a pilot bioequivalence study take?
6. What happens if the pilot shows high variability?
More BA/BE Studies Services
Every study type under one roof — explore the rest of our ba/be studies capabilities.
Fed & Fasting BE
Food-effect and fed BE studies that show your product performs against the reference in both dosing states.
Patient BE Studies
BE studies in patients when healthy-volunteer dosing is unsafe — cytotoxic, oncology, and high-risk products.
Biosimilar PK Studies
Comparative pharmacokinetic similarity studies for biosimilars, backed by large-molecule LC-MS/MS.
Population BE
Designs and statistics for when average bioequivalence alone cannot answer the prescribability question.
Postmenopausal Studies
Special-population BA/BE studies in postmenopausal women for hormone and women’s-health products.
Transdermal Patch BE
TDS bioequivalence programs covering PK, adhesion, irritation, sensitization, and residual drug analysis.
Nasal Spray BE
Device-based BE combining in vitro performance testing with in vivo PK under a weight-of-evidence approach.
Bioanalytical Services
LC-MS/MS method development, ICH M10 validation, and study sample analysis — the lab behind every study.
Discuss Your Pilot BE Studies Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.